Sina Rashedi, Christie M Greason, Parham Sadeghipour, Azita H Talasaz, Michelle L O'Donoghue, David Jimenez, Manuel Monreal, Christopher D Anderson, Mitchell S V Elkind, Lisa M Baumann Kreuziger, Irene M Lang, Samuel Z Goldhaber, Stavros V Konstantinides, Gregory Piazza, Harlan M Krumholz, Eugene Braunwald, Behnood Bikdeli
Fibrinolytic agents catalyze the conversion of the inactive proenzyme plasminogen into the active protease plasmin, degrading fibrin within the thrombus and recanalizing occluded vessels. The history of these medications dates to the discovery of the first fibrinolytic compound, streptokinase, from bacterial cultures in 1933. Over time, researchers identified two other plasminogen activators in human samples, namely urokinase and tissue plasminogen activator (tPA). Subsequently, tPA was cloned using recombinant DNA methods to produce alteplase...
March 1, 2024: Seminars in Thrombosis and Hemostasis